TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Petmed Express ( (PETS) ) has provided an update.
On November 26, 2025, PetMed Express announced an amendment to its shareholder rights plan, extending its expiration date to December 2, 2026, to protect shareholder investments and prevent control acquisition without a premium. Additionally, the Board approved a salary increase for Douglas Krulik, the Interim Principal Financial Officer, effective August 30, 2025, and entered into a severance agreement with him.
The most recent analyst rating on (PETS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express faces significant financial and technical challenges. The company’s declining revenues and profitability issues are compounded by bearish technical indicators and a negative P/E ratio. These factors suggest a cautious outlook for the stock.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
Founded in 1996, PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector. As a national online pharmacy licensed across all 50 states, PetMeds offers a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements, through its PETS family of brands and PetCareRx subsidiary.
Average Trading Volume: 136,773
Technical Sentiment Signal: Sell
Current Market Cap: $34.26M
For an in-depth examination of PETS stock, go to TipRanks’ Overview page.